deltatrials
Completed PHASE3 NCT01964430

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the Apact Study)

A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma

Sponsor: Celgene

Conditions Antimetabolites, Antineoplastic Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Gemcitabine Neoplasms Neoplasms by Site Pancreatic Diseases Pancreatic Neoplasms
Interventions Gemcitabine nab-Paclitaxel
Updated 24 times since 2017 Last updated: Jun 13, 2023 Started: Mar 28, 2014 Primary completion: Jun 30, 2022 Completion: Jun 30, 2022

This PHASE3 trial investigates Antimetabolites, Antineoplastic and Digestive System Diseases and is currently completed. Celgene leads this study, which shows 24 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2023 — Jul 2023 [monthly]

    Completed PHASE3

▶ Show 19 earlier versions

  1. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

  2. Nov 2022 — Dec 2022 [monthly]

    Completed PHASE3

  3. Sep 2022 — Nov 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Jan 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  5. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Feb 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Sep 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Apr 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  9. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  10. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  11. Nov 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  13. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  14. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  15. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  16. Jun 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE3

  17. Mar 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  18. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting PHASE3

  19. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene
Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark, Amsterdam, Netherlands, Ancona, Italy, Angers, France, Ann Arbor, United States, Atlanta, United States, Aurora, United States, Barcelona, Spain, Basking Ridge, United States, Bayern, Germany and 143 more location s